IGF-I treatment in adults with type 1 diabetes -: Effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp

被引:31
作者
Carroll, PV
Christ, ER
Umpleby, AM
Gowrie, I
Jackson, N
Bowes, SB
Hovorka, R
Croos, P
Sönksen, PH
Russell-Jones, DL
机构
[1] St Thomas Hosp, Div Med, London, England
[2] City Univ London, Ctr Measurement & Informat Med, London EC1V 0HB, England
关键词
D O I
10.2337/diabetes.49.5.789
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetes is associated with abnormalities of the growth hormone (GH)-IGF-I axis. Such abnormalities include decreased circulating levels of IGF-I. We studied the effects of IGF-I therapy (40 mu g . kg(-1) . day(-1)) on protein and glucose metabolism in adults with type I diabetes in a randomized placebo-controlled trial. A total of 12 subjects participated, and each subject was studied at baseline and after 7 days of treatment, both in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Protein and glucose metabolism were assessed using infusions of [1-C-13]leucine and [6-6-H-2(2)]glucose. IGF-I administration resulted in a 51% rise in circulating IGF-I levels (P < 0.005) and a 56% decrease in the mean overnight GH concentration (P < 0.05). After IGF-I treatment, a decrease in the overnight insulin requirement (0.26 +/- 0.07 vs. 0.17 +/- 0.06 U/kg, P < 0.05) and an increase in the glucose infusion requirement were observed during the hyperinsulinemic clamp (similar to 67%, P < 0.05). nasal glucose kinetics were unchanged, but an increase in insulin-stimulated peripheral glucose disposal was observed after IGF-I therapy (37 +/- 6 vs. 52 +/- 10 mu mol . kg(-1) . min(-1), P < 0.05). IGF-I administration increased the basal metabolic clearance rate for leucine (similar to 28%, P < 0.05) and resulted in a net increase in leucine balance, both in the basal state and during the hyperinsulinemic amino acid clamp (-0.17 +/- 0.03 vs. -0.10 +/- 0.02, P < 0.01, and 0.25 +/- 0.08 vs. 0.40 +/- 0.06, P < 0.05, respectively). No changes in these variables were recorded in the subjects after administration of placebo. These findings demonstrated that IGF-I replacement resulted in significant alterations in glucose and protein metabolism in the basal and insulin-stimulated states. These effects were associated with increased insulin sensitivity, and they underline the major role of IGF-I in protein and glucose metabolism in type 1 diabetes.
引用
收藏
页码:789 / 796
页数:8
相关论文
共 44 条
[1]   Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus [J].
Acerini, CL ;
Patton, CM ;
Savage, MO ;
Kernell, A ;
Westphal, O ;
Dunger, DB .
LANCET, 1997, 350 (9086) :1199-1204
[2]   THE EFFECTS OF SUBCUTANEOUS INSULIN-LIKE GROWTH-FACTOR-I INFUSION IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
BACH, MA ;
CHIN, E ;
BONDY, CA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (04) :1040-1045
[3]   EUGLYCEMIC HYPERINSULINEMIA AUGMENTS AMINO-ACID-UPTAKE BY HUMAN LEG TISSUES DURING HYPERAMINOACIDEMIA [J].
BENNET, WM ;
CONNACHER, AA ;
SCRIMGEOUR, CM ;
JUNG, RT ;
RENNIE, MJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (02) :E185-E194
[4]   INSULIN REGULATES INSULIN-LIKE GROWTH FACTOR-I MESSENGER-RNA IN RAT HEPATOCYTES [J].
BONISCHNETZLER, M ;
SCHMID, C ;
MEIER, PJ ;
FROESCH, ER .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (06) :E846-E851
[5]   COMPARISON OF THE METABOLIC EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR-I AND INSULIN - DOSE-RESPONSE RELATIONSHIPS IN HEALTHY-YOUNG AND MIDDLE-AGED ADULTS [J].
BOULWARE, SD ;
TAMBORLANE, WV ;
RENNERT, NJ ;
GESUNDHEIT, N ;
SHERWIN, RS .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) :1131-1139
[6]   DIVERSE EFFECTS OF INSULIN-LIKE GROWTH-FACTOR I ON GLUCOSE, LIPID, AND AMINO-ACID-METABOLISM [J].
BOULWARE, SD ;
TAMBORLANE, WV ;
MATTHEWS, LS ;
SHERWIN, RS .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (01) :E130-E133
[7]   The effect of recombinant human growth hormone on glucose and leucine metabolism in Cushing's syndrome [J].
Bowes, SB ;
Umpleby, M ;
Cummings, MH ;
Jackson, NC ;
Carroll, PV ;
Lowy, C ;
Sonksen, PH ;
RussellJones, DL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) :243-246
[8]   rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM [J].
Carroll, PV ;
Umpleby, M ;
Ward, GS ;
Imuere, S ;
Alexander, E ;
Dunger, D ;
Sonksen, PH ;
RussellJones, DL .
DIABETES, 1997, 46 (09) :1453-1458
[9]   EFFECT OF INSULIN AND PLASMA AMINO-ACID-CONCENTRATIONS ON LEUCINE METABOLISM IN MAN - ROLE OF SUBSTRATE AVAILABILITY ON ESTIMATES OF WHOLE-BODY PROTEIN-SYNTHESIS [J].
CASTELLINO, P ;
LUZI, L ;
SIMONSON, DC ;
HAYMOND, M ;
DEFRONZO, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (06) :1784-1793
[10]   THE EFFECTS OF RECOMBINANT INSULIN-LIKE GROWTH FACTOR-I ADMINISTRATION ON GROWTH-HORMONE LEVELS AND INSULIN REQUIREMENTS IN ADOLESCENTS WITH TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
CHEETHAM, TD ;
JONES, J ;
TAYLOR, AM ;
HOLLY, J ;
MATTHEWS, DR ;
DUNGER, DB .
DIABETOLOGIA, 1993, 36 (07) :678-681